Logotipo do repositório
 

Publicação:
Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis

dc.contributor.authorMaltempe, Flaviane Granero
dc.contributor.authorCaleffi-Ferracioli, Katiany Rizzieri
dc.contributor.authorRibeiro do Amaral, Renata Claro
dc.contributor.authorDemitto, Fernanda de Oliveira
dc.contributor.authorDias Siqueira, Vera Lucia
dc.contributor.authorLima Scodro, Regiane Bertin de
dc.contributor.authorHirata, Mario Hiroyuki
dc.contributor.authorPavan, Fernando Rogerio [UNESP]
dc.contributor.authorCardoso, Rosilene Fressatti
dc.contributor.institutionUniversidade Estadual de Maringá (UEM)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-26T17:31:23Z
dc.date.available2018-11-26T17:31:23Z
dc.date.issued2017-05-01
dc.description.abstractBackground: Linezolid (LZD) is not commonly used for treating tuberculosis (TB), but in some patients with drug-resistant TB it is being used. However, the in vitro LZD activity, in combination with rifampicin (RIF) against Mycobacterium tuberculosis has not been fully elucidated. Aims: The aim of this study was to evaluate the in vitro activity of RIF/LZD combination against M. tuberculosis clinical isolates. Materials and methods: The activity of the RIF/LZD combination was firstly determined in M. tuberculosis H(37)Rv, 14 susceptible, 9 isoniazid nonresistant and 14 multi-drug resistant (MDR) M. tuberculosis clinical isolates by modified checkerboard assay, Resazurin Drugs Combination Microtiter Assay (REDCA). After, the Time Kill Curve Assay, at 0.5 x MIC of drugs, in combination and alone, was performed in M. tuberculosis H(37)Rv and 8 (20.5%) of those clinical isolates, which the RIF/LZD combination showed to have synergistic effect by the checkerboard assay. Results and conclusion: By Time Kill Curve Assay, we could observe in M. tuberculosis H(37)Rv and susceptible isolates, that LZD alone, at sub inhibitory concentration, has poor effect on the bacillus death. In some cases, the bacillus growth stayed constant while in others showed regrowth at the eighth day of drug exposure. RIF alone exhibits potent concentration-dependent bactericidal activity, and was strongly dependent by the drug exposure time. The RIF/LZD combination accomplished a bacteriostatic effect in the reference strain and susceptible isolates. For the RIF resistant isolates, the RIF/LZD combination did not enhance the effect in killing bacillus. In this sense, additional, in vitro and in vivo studies are needed to evaluate the effect of RIF/LZD combination in order to better understand the adjunctive action of LZD in the treatment of TB and prevent the emergence of mutants with resistance to the available anti-TB drugs. (C) 2017 Elsevier Ltd. All rights reserved.en
dc.description.affiliationUniv Estadual Maringa, Postgrad Biosci & Physiopathol, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil
dc.description.affiliationUniv Estadual Maringa, Dept Clin Anal & Biomed, Lab Teaching & Res Clin Anal LEPAC, Lab Med Bacteriol, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil
dc.description.affiliationUniv Estadual Maringa, Postgrad Hlth Sci, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil
dc.description.affiliationUniv Sao Paulo, Sch Pharmaceut Sci, BR-05508900 Sao Paulo, Brazil
dc.description.affiliationUniv Estadual Paulista, Dept Biol Sci, Sch Pharmaceut Sci, BR-14800901 Sao Paulo, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Dept Biol Sci, Sch Pharmaceut Sci, BR-14800901 Sao Paulo, Brazil
dc.format.extent24-29
dc.identifierhttp://dx.doi.org/10.1016/j.tube.2017.02.004
dc.identifier.citationTuberculosis. Edinburgh: Churchill Livingstone, v. 104, p. 24-29, 2017.
dc.identifier.doi10.1016/j.tube.2017.02.004
dc.identifier.fileWOS000401127100004.pdf
dc.identifier.issn1472-9792
dc.identifier.urihttp://hdl.handle.net/11449/162785
dc.identifier.wosWOS:000401127100004
dc.language.isoeng
dc.publisherChurchill Livingstone
dc.relation.ispartofTuberculosis
dc.relation.ispartofsjr1,264
dc.rights.accessRightsAcesso abertopt
dc.sourceWeb of Science
dc.subjectDrug resistance
dc.subjectTreatment
dc.subjectTuberculosis
dc.subjectLinezolid and rifampicin combination
dc.titleActivity of rifampicin and linezolid combination in Mycobacterium tuberculosisen
dc.typeArtigopt
dcterms.rightsHolderChurchill Livingstone
dspace.entity.typePublication
relation.isDepartmentOfPublication5004bcab-94af-4939-b980-091ae9d0a19e
relation.isDepartmentOfPublication.latestForDiscovery5004bcab-94af-4939-b980-091ae9d0a19e
unesp.departmentCiências Biológicas - FCFpt

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
WOS000401127100004.pdf
Tamanho:
565.94 KB
Formato:
Adobe Portable Document Format
Descrição: